If you enjoy this content, please share it with a colleague
Volpara Solutions Limited
RELATED CONTENT
November 19, 2020 — Radiologists around the world will have access to a first-of-its-kind online breast density training ...
October 19, 2020 — Volpara Solutions, a leader in AI-powered breast density assessment, announced that it has changed ...
October 15, 2020 — Fujifilm Medical Systems U.S.A., Inc., a leading provider of diagnostic imaging and medical ...
June 9, 2020 — More than 75 percent of hospitals and imaging centers that perform mammography across the United States ...
April 7 2020 — Volpara Solutions announced it is collaborating with DetectED-X, an online radiology training and ...
Celebrating its 10th Anniversary in 2019, Volpara Solutions remains committed to helping breast imaging centers achieve ...
Volpara Solutions and ScreenPoint Medical BV signed an agreement under which Volpara will sell ScreenPoint's Transpara products to breast imaging clinics in the United States, Australia, New Zealand and parts of Asia. Transpara is designed to assist radiologists with the reading of mammograms and is one of the first next-generation artificial intelligence (AI) applications for detecting breast cancer in screening mammograms to gain 510(k) clearance from the U.S. Food & Drug Administration (FDA).
Volpara Health Technologies, Volpara Solutions' parent company, has signed a binding agreement to acquire U.S.-based MRS Systems Inc. (MRS).
Research has demonstrated use of Volpara Solutions' VolparaDensity software in combination with the Tyrer-Cuzick Breast Cancer Risk Evaluation Tool improves breast cancer risk stratification. The research suggests VolparaDensity could be used to help guide personalized medicine through risk-adapted screening.
Volpara Solutions announced the launch of an expanded agreement enabling the worldwide distribution of its VolparaDensity software by GE Healthcare.